AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

12.750

-0.820-6.04%

Volume:481.62K

Turnover:6.24M

Market Cap:1.61B

PE:11.11

High:13.500

Open:13.330

Low:12.750

Close:13.570

52wk High:22.985

52wk Low:8.610

Shares:126.64M

Float Shares:108.39M

Volume Ratio:0.79

T/O Rate:0.44%

Dividend:- -

Dividend Rate:- -

EPS(TTM):1.148

EPS(LYR):1.086

ROE:54.96%

ROA:41.13%

PB:4.99

PE(LYR):11.74

Loading ...

Overview Company News Filings

NewMarket (NEU) Margin Decline Challenges Long Term Earnings Growth Narrative

Simply Wall St.

Neuren Pharmaceuticals (ASX:NEU) Valuation Check As New Share Buy-Back Targets 5% Of Share Capital

Simply Wall St.

Earnings Flash (NEU) NewMarket Posts Q4 EPS of $8.65

MT Newswires Live

Neuren Pharmaceuticals to Commence New On-Market Share Buy-Back Program

MT Newswires Live

Neuren Pharmaceuticals - Buy-Back Program Will Not Exceed 5% of Total Shares on Issue 12 Months Prior to Commencement of Buy- Back

THOMSON REUTERS

Neuren's Regulatory Hurdles for Trofinetide May Push Back EU Royalties, Says Jefferies

MT Newswires Live

BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cuts

Neuren Doses First Patient in Drug Candidate Trial for Treatment of Neurological Disorder

MT Newswires Live

Slammed 30% Neuren Pharmaceuticals Limited (ASX:NEU) Screens Well Here But There Might Be A Catch

Simply Wall St.

BUZZ-Australia's Neuren Pharmaceuticals extends plunge on regulatory hurdles

Neuren Pharmaceuticals Says US Extends Rare Pediatric Disease Voucher Program

MT Newswires Live

Neuren Pharmaceuticals Says US FDA Provides Guidance On Clinical Study OF Drug Candidate For Treatment Of Hypoxic Ischemic Encephalopathy

MT Newswires Live

Neuren Pharmaceuticals (ASX:NEU) Is Down 16.1% After EMA Setback on Trofinetide Approval Prospects

Simply Wall St.

Neuren Pharmaceuticals Ltd - Received Feedback on Ind Application Plan for Hypoxic Ischemic Encephalopathy

THOMSON REUTERS

Neuren Pharmaceuticals - U.S. FDA Determined Meetings for Hie and Pths as Written Responses Only

THOMSON REUTERS

Neuren Pharmaceuticals Requests Trading Halt Ahead of FDA Feedback on NNZ-2591

MT Newswires Live

BRIEF-Neuren Pharmaceuticals Seeks Trading Halt

Neuren Pharmaceuticals Ltd - Seeks Trading Halt Pending FDA Feedback on Nnz-2591

THOMSON REUTERS

BRIEF-Neuren Pharmaceuticals Informed Of Negative Trend Vote On MAA For Trofinetide

BUZZ-Australia's Neuren sinks on setback for Rett treatment drug application from European regulator

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NEU.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":12.75,"timestamp":1770959520000,"preClose":13.57,"halted":0,"volume":481622,"delay":0,"changeRate":-0.06042741341193812,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":108394581,"shares":126639526,"eps":1.147709,"marketStatus":"Market Closed","change":-0.82,"latestTime":"02-13 16:12:00 AEDT","open":13.33,"high":13.5,"low":12.75,"amount":6238813,"amplitude":0.055269,"askPrice":13.19,"askSize":3852,"bidPrice":12.74,"bidSize":228,"shortable":3,"etf":0,"ttmEps":1.147709,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1771196400000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":13.57,"openAndCloseTimeList":[[1770937200000,1770958800000]],"volumeRatio":0.7875168580845279,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":108394581,"roa":"41.13%","roe":"54.96%","lyrEps":1.086099,"volumeRatio":0.7875168580845279,"shares":126639526,"dividePrice":0,"high":13.5,"amplitude":0.055269,"preClose":13.57,"low":12.75,"week52Low":8.61,"pbRate":"4.99","psRate":"7.38","week52High":22.985,"institutionHeld":0,"latestPrice":12.75,"committee":-0.888235,"eps":1.147709,"divideRate":0,"volume":481622,"delay":0,"ttmEps":1.147709,"open":13.33,"prevYearClose":18.61,"prevWeekClose":12.52,"prevMonthClose":16.69,"prevQuarterClose":18.61,"fiveDayClose":12.52,"twentyDayClose":19.71,"sixtyDayClose":18.89},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2611185336","title":"NewMarket (NEU) Margin Decline Challenges Long Term Earnings Growth Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2611185336","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611185336?lang=en_us&edition=fundamental","pubTime":"2026-02-13 10:34","pubTimestamp":1770950083,"startTime":"0","endTime":"0","summary":"NewMarket (NEU) has wrapped up FY 2025 with fourth quarter revenue of US$635.4 million and basic EPS of US$8.65, anchored by net income of US$81.3 million, alongside trailing twelve month revenue of US$2.7 billion and basic EPS of US$44.44. Over recent quarters, the company has seen revenue move from US$700.9 million and EPS of US$13.26 in Q1 2025 through to US$698.5 million and EPS of US$11.84 in Q2, US$690.3 million and EPS of US$10.67 in Q3, and then US$635.4 million and EPS of US$8.65 in...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-margin-decline-challenges-long-term-earnings-g","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-margin-decline-challenges-long-term-earnings-g","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU","NEU.AU"],"gpt_icon":0},{"id":"2611896051","title":"Neuren Pharmaceuticals (ASX:NEU) Valuation Check As New Share Buy-Back Targets 5% Of Share Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2611896051","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611896051?lang=en_us&edition=fundamental","pubTime":"2026-02-13 10:30","pubTimestamp":1770949801,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals (ASX:NEU) has announced a new share buy-back program, authorising repurchases of up to 6,350,631 shares, or 5% of its issued capital, through to March 2027.\nSee our latest analysis for Neuren Pharmaceuticals.\nThe buy-back comes after a sharp 30 day share price return of around a 30% decline and a 90 day share price return of about a 29% decline, even though the 1 year and multi year total shareholder returns remain positive and very strong. This suggests recent selling...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-valuation-check-as-new-share-b","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-valuation-check-as-new-share-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4109","DCF","BK7508","NEU.AU","NEU","BK7096"],"gpt_icon":0},{"id":"2610496295","title":"Earnings Flash (NEU) NewMarket Posts Q4 EPS of $8.65","url":"https://stock-news.laohu8.com/highlight/detail?id=2610496295","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610496295?lang=en_us&edition=fundamental","pubTime":"2026-02-12 06:24","pubTimestamp":1770848670,"startTime":"0","endTime":"0","summary":"Earnings Flash (NEU) NewMarket Posts Q4 EPS of $8.65","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","NEU"],"gpt_icon":0},{"id":"2610983756","title":"Neuren Pharmaceuticals to Commence New On-Market Share Buy-Back Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2610983756","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610983756?lang=en_us&edition=fundamental","pubTime":"2026-02-11 14:47","pubTimestamp":1770792440,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  disclosed a new on-market share buy-back program with a period of up to 12 months, which will be conducted under section 65 of the New Zealand Companies Act 1993 and will not exceed 5% of the total shares on issue 12 months before the commencement of the buy-back, according to a Wednesday Australian bourse filing.\"The board views the current share price as materially undervaluing Neuren's assets, relative to internal analyses and the range of recently published analyst valuations,\" said Chair Patrick Davies.Shares purchased under the buy-back will be cancelled upon acquisition, reducing the number of shares on issue, and the number of shares purchased under the buy-back will be less than the \"10/12\" limit prescribed in the Australian Corporations Act and will not require shareholder approval, the filing added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NEU.AU","BK7508"],"gpt_icon":0},{"id":"2610988807","title":"Neuren Pharmaceuticals -  Buy-Back Program Will Not Exceed 5% of Total Shares on Issue 12 Months Prior to Commencement of Buy- Back","url":"https://stock-news.laohu8.com/highlight/detail?id=2610988807","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610988807?lang=en_us&edition=fundamental","pubTime":"2026-02-11 14:00","pubTimestamp":1770789635,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z61NR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2609384536","title":"Neuren's Regulatory Hurdles for Trofinetide May Push Back EU Royalties, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2609384536","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609384536?lang=en_us&edition=fundamental","pubTime":"2026-02-06 08:13","pubTimestamp":1770336816,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  facing regulatory uncertainty in the European Union  for its investigational drug trofinetide to treat Rett syndrome may delay royalties from sales in the region, Jefferies said in a note on Thursday.The European Medicines Agency  Committee for Medicinal Products for Human Use  gave a negative trend vote this week on the drug candidate's market authorization application, possibly due to concerns about the effect size in the confirmatory trial.Jefferies said the negative trend vote is an early indication that the regulatory authority might issue a negative opinion on the application at the final vote.The investment firm now expects royalties from EU sales of trofinetide to kick in the fourth quarter of fiscal 2026, and not second quarter.Meanwhile, it projects Neuren's experimental drug NNZ-2591 for treating Pitt-Hopkins Syndrome, a rare neurodevelopmental disorder, will receive reimbursement approval in the US in fiscal 2029.Jefferies lowered the company's fisca","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","NEU.AU","BK4081","BK7129","BK7096","CHMP","EMA","BK4087","EMA.AU","BK4156"],"gpt_icon":0},{"id":"2609533926","title":"BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cuts","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533926","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609533926?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:39","pubTimestamp":1770334764,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cutsUpdates** Neuren Pharmaceuticals NEU.AX slips 3.41% to A$12.750, heading toward a tenth straight day of losses** St","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nL6N3Z11HG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","JEF","BK4127","BK7096","ACAD","BK7508","BK4139","LU2065171402.SGD","NEU.AU","BK4559","LU2065170008.USD","LU2065171311.SGD"],"gpt_icon":0},{"id":"2609533478","title":"Neuren Doses First Patient in Drug Candidate Trial for Treatment of Neurological Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533478","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609533478?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:15","pubTimestamp":1770333305,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  dosed the first patient in its Koala Phase 3 clinical trial of its drug candidate NNZ-2591 for the treatment of Phelan-McDermid syndrome , a neurological disorder with no treatment options, according to a Friday filing with the Australian bourse.The trial evaluates the safety and efficacy of NNZ-2591 in about 160 children aged three to 12 years with PMS, the filing said.Most of the participants in the trial are expected to start dosing or start screening during February and March, the filing added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2609756530","title":"Slammed 30% Neuren Pharmaceuticals Limited (ASX:NEU) Screens Well Here But There Might Be A Catch","url":"https://stock-news.laohu8.com/highlight/detail?id=2609756530","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609756530?lang=en_us&edition=fundamental","pubTime":"2026-02-06 04:55","pubTimestamp":1770324925,"startTime":"0","endTime":"0","summary":"The Neuren Pharmaceuticals Limited ( ASX:NEU ) share price has fared very poorly over the last month, falling by a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/slammed-30-neuren-pharmaceuticals-limited-asxneu-screens-wel","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/slammed-30-neuren-pharmaceuticals-limited-asxneu-screens-wel","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4109","NEU","NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2609346456","title":"BUZZ-Australia's Neuren Pharmaceuticals extends plunge on regulatory hurdles","url":"https://stock-news.laohu8.com/highlight/detail?id=2609346456","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609346456?lang=en_us&edition=fundamental","pubTime":"2026-02-05 10:51","pubTimestamp":1770259908,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren Pharmaceuticals extends plunge on regulatory hurdles** Shares of Neuren Pharmaceuticals NEU.AX plunges as much as 10.7% to A$13.06** Biotech says FDA will only provide written responses for NNZ-2591 drug development meetings, not face-to-face discussions as requested** Drug targets hypoxic ischemic encephalopathy and Pitt Hopkins syndrome** Stock fell 10% on Feb 3 on setback for Rett treatment drug application from European regulator, trading halt on Feb 4 pending FDA update","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nL4N3Z10B1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2609225316","title":"Neuren Pharmaceuticals Says US Extends Rare Pediatric Disease Voucher Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2609225316","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609225316?lang=en_us&edition=fundamental","pubTime":"2026-02-05 05:53","pubTimestamp":1770242003,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said the US Congress on Tuesday reauthorized the Rare Pediatric Disease Priority Review Voucher  program, extending it through Sept. 30, 2029, according to a Thursday Australian bourse filing.The PRV program grants a voucher to developers whose drug receives approval from the US Food and Drug Administration  for a designated rare pediatric disease, which can be used for priority review of another drug or be sold or transferred, per the filing.The company's NNZ-2591 has rare pediatric disease designations for Phelan-McDermid, Pitt Hopkins, and Angelman syndromes, and US FDA approval in any of these would earn a voucher, with full ownership and entitlement to all sale proceeds, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2608333772","title":"Neuren Pharmaceuticals Says US FDA Provides Guidance On Clinical Study OF Drug Candidate For Treatment Of Hypoxic Ischemic Encephalopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2608333772","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608333772?lang=en_us&edition=fundamental","pubTime":"2026-02-04 14:43","pubTimestamp":1770187413,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals (ASX:NEU) said that the US Food and Drug Administration (FDA) generally accepted the investigational new study-opening clinical study of the pharmacokinetics, tolerability and s","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2608549573","title":"Neuren Pharmaceuticals (ASX:NEU) Is Down 16.1% After EMA Setback on Trofinetide Approval Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2608549573","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608549573?lang=en_us&edition=fundamental","pubTime":"2026-02-04 14:24","pubTimestamp":1770186248,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals recently received a negative trend vote from the European Medicines Agency’s Committee for Medicinal Products for Human Use on trofinetide’s marketing authorisation application for Rett syndrome in Europe, and Acadia plans to request a re-examination of the decision.\nThis setback highlights how regulatory assessments can differ across regions even for a rare-disease therapy already approved in the US, Canada and Israel, adding...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-is-down-161-after-ema-setback","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-is-down-161-after-ema-setback","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4081","BK4109","EMA","NEU","NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2608332981","title":"Neuren Pharmaceuticals Ltd - Received Feedback on Ind Application Plan for Hypoxic Ischemic Encephalopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2608332981","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608332981?lang=en_us&edition=fundamental","pubTime":"2026-02-04 14:09","pubTimestamp":1770185388,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nFWN3YZ15K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEU.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2608332688","title":"Neuren Pharmaceuticals  - U.S. FDA Determined Meetings for Hie and Pths as Written Responses Only","url":"https://stock-news.laohu8.com/highlight/detail?id=2608332688","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608332688?lang=en_us&edition=fundamental","pubTime":"2026-02-04 14:09","pubTimestamp":1770185388,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nFWN3YZ15K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2608937381","title":"Neuren Pharmaceuticals Requests Trading Halt Ahead of FDA Feedback on NNZ-2591","url":"https://stock-news.laohu8.com/highlight/detail?id=2608937381","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608937381?lang=en_us&edition=fundamental","pubTime":"2026-02-04 07:52","pubTimestamp":1770162745,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  has requested an immediate trading halt on its shares, pending an update regarding US Food and Drug Administration  feedback on its NNZ-2591 treatment for Pitt Hopkins syndrome and hypoxic-ischemic encephalopathy, according to a Wednesday Australian bourse filing.The trading halt will remain in place until either the market opens on Friday or the company releases an update, whichever comes first, the filing added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2608389129","title":"BRIEF-Neuren Pharmaceuticals Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2608389129","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608389129?lang=en_us&edition=fundamental","pubTime":"2026-02-04 07:15","pubTimestamp":1770160538,"startTime":"0","endTime":"0","summary":"BRIEF-Neuren Pharmaceuticals Seeks Trading HaltFeb 4 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX:SEEKS TRADING HALT PENDING FDA FEEDBACK ON NNZ-2591Further company coverage: NEU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ188:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NEU.AU","BK7508"],"gpt_icon":0},{"id":"2608389123","title":"Neuren Pharmaceuticals Ltd - Seeks Trading Halt Pending FDA Feedback on Nnz-2591","url":"https://stock-news.laohu8.com/highlight/detail?id=2608389123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608389123?lang=en_us&edition=fundamental","pubTime":"2026-02-04 07:15","pubTimestamp":1770160511,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ188:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2608811019","title":"BRIEF-Neuren Pharmaceuticals Informed Of Negative Trend Vote On MAA For Trofinetide","url":"https://stock-news.laohu8.com/highlight/detail?id=2608811019","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608811019?lang=en_us&edition=fundamental","pubTime":"2026-02-03 08:44","pubTimestamp":1770079483,"startTime":"0","endTime":"0","summary":"BRIEF-Neuren Pharmaceuticals Informed Of Negative Trend Vote On MAA For TrofinetideFeb 3  - Neuren Pharmaceuticals NEU.AX:WAS INFORMED OF A NEGATIVE TREND VOTE ON ITS MAA FOR TROFINETIDEACADIA TO REQUEST RE-EXAMINATION OF CHMP OPINIONACADIA WAS INFORMED BY COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE OF EUROPEAN MEDICINES AGENCYFurther company coverage: NEU.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YY1PG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2608819507","title":"BUZZ-Australia's Neuren sinks on setback for Rett treatment drug application from European regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2608819507","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608819507?lang=en_us&edition=fundamental","pubTime":"2026-02-03 08:01","pubTimestamp":1770076916,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren sinks on setback for Rett treatment drug application from European regulator** Shares of biopharma firm Neuren Pharmaceuticals NEU.AX tumble as much as 22.1% to A$12.660, posti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nL6N3YY1AW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACAD","BK7096","BK7508","BK4139","NEU.AU","LU2065171402.SGD","LU2065171311.SGD","LU2065170008.USD","LU2065169927.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":60,"code":"91000000","status":"200"}]}}